Analysis

Sab Biotherapeutics, Inc. (SABS) Stock Analysis

Sab Biotherapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to SABS.

websiteSABS/analysis/SABS

Sab Biotherapeutics, Inc.

Sab Biotherapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to SABS.

Stock profile

Ticker

SABS

Asset type

Stock

Market cap

$305.9M

Sector

Health Technology

Industry

Biotechnology

Currency

USD

Ticker listings

Sab Biotherapeutics, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • SABS primary listing

Latest Sab Biotherapeutics, Inc. news

SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully human multi-specific ATG for newly diagnosed Stage 3 T1DMIAMI, May 29, 2026 (G...

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SAB BIO Reports Q1 2026 Financial Results and Recent Business

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobul...

Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, S...

GAITHERSBURG, Md., April 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a multi-year agreement with SAB Biotherapeutics, Inc. (Nasdaq: SABS,...

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1...

All 4 T1D participants receiving SAB-142 showed C-peptide preservation with 3 of the 4 participants showing a super responder profile concomitant with T cell exhaustion T1D part...

Research sections

Valuation

Review valuation context for Sab Biotherapeutics, Inc..

Future growth

Review future growth context for Sab Biotherapeutics, Inc..

Past performance

Review past performance context for Sab Biotherapeutics, Inc..

Financial health

Review financial health context for Sab Biotherapeutics, Inc..

Dividend

Review dividend context for Sab Biotherapeutics, Inc..

Management

Review management context for Sab Biotherapeutics, Inc..

Ownership

Review ownership context for Sab Biotherapeutics, Inc..

Other information

Review other information context for Sab Biotherapeutics, Inc..

Community

Review community context for Sab Biotherapeutics, Inc..